The Food and Drug Administration (FDA) approved Pfizer’s treatment for a rare genetic bleeding disorder, marking the company’s first gene therapy clearance in the U.S. Known as Beqvez, the drug is sanctioned for adults with moderate to severe hemophilia B who meet specific criteria. Despite the milestone, Beqvez comes with a substantial price tag of… Continue reading FDA approves Pfizer’s first gene therapy for rare inherited bleeding disorder

Merck reported strong first-quarter revenue and adjusted earnings, driven by robust sales of Keytruda, its blockbuster cancer drug, and vaccine products. The company raised its full-year revenue and adjusted earnings forecasts, expecting sales between $63.1 billion and $64.3 billion and adjusted earnings of $8.53 to $8.65 per share. Despite a one-time charge related to the… Continue reading Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales

Bristol Myers Squibb’s first-quarter revenue exceeded expectations, driven by strong sales of its blood cancer treatment Revlimid and blood thinner Eliquis. Despite this, the company reported a quarterly loss due to one-time charges linked to recent deals and announced plans to cut $1.5 billion in costs by 2025, reallocating funds into drug development. The cost-saving… Continue reading Bristol Myers Squibb beats on revenue, launches $1.5 billion cost cuts as it posts quarterly loss

More than 3 million people enrolled in Medicare could potentially benefit from coverage of the weight loss drug Wegovy, now that it’s approved in the U.S. for heart health as well, according to an analysis by the Kaiser Family Foundation (KFF). However, some eligible beneficiaries might still encounter out-of-pocket costs for this expensive drug, as… Continue reading More than 3 million Medicare patients could be eligible for coverage of Wegovy to reduce heart disease risks, study says

Biogen reported first-quarter profits that surpassed expectations, largely attributed to successful cost-cutting measures and increased sales of its Alzheimer’s drug, Leqembi. Despite a sluggish launch, Leqembi’s sales surged to approximately $19 million for the quarter, surpassing analyst estimates of $11 million. The number of patients using Leqembi nearly doubled since the end of 2023, with… Continue reading Biogen tops profit estimates as cost cuts take hold, Alzheimer’s drug Leqembi launch picks up

The increasing popularity of GLP-1 drugs, renowned for their effectiveness in weight loss and diabetes management, is not only impacting consumers’ health but also reshaping their spending habits, particularly in the food industry. According to a Morgan Stanley survey, a significant proportion of GLP-1 drug users are cutting down on dining out and ordering takeout,… Continue reading Most people on weight loss drugs are spending less on restaurants and takeout, survey says

Dr. Jordan Shlain has redefined medical care with Private Medical, likening it to a “family office for your health,” emphasizing the preservation of health as paramount, much like preserving wealth in family offices. Private Medical offers a highly personalized, all-in-one service akin to sophisticated family offices for investments, managing a family’s entire health portfolio, from… Continue reading Meet the private doctor to the wealthy — at $40,000 a year

Anne Wojcicki, CEO of 23andMe, is contemplating the prospect of privatizing the genetic testing company following a significant plunge in its stock price, which has dropped by over 95% from its peak in 2021. According to a recent filing with the Securities and Exchange Commission, Wojcicki is collaborating with advisors and intends to engage with… Continue reading 23andMe CEO Anne Wojcicki considers taking company private

Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders, announced today that the U.S. Food & Drug Administration (“FDA”) has accepted the Company’s meeting request for the Revive… Continue reading Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product

Eli Lilly’s weight loss drug Zepbound has shown promise in treating obstructive sleep apnea (OSA), a common sleep-related breathing disorder, according to preliminary data from two late-stage clinical trials. The pharmaceutical giant plans to present the results at an upcoming medical conference and seek regulatory approval. Zepbound was found to be more effective than a… Continue reading Eli Lilly’s weight loss drug Zepbound shows promise as a sleep apnea treatment in late-stage trials

Johnson & Johnson (J&J) reported first-quarter adjusted earnings exceeding Wall Street expectations, with a surge in sales in its medical devices division driving this performance. The division, offering devices for surgeries, orthopedics, and vision, experienced heightened demand for nonurgent surgeries among older adults, resulting in elevated procedure levels post-pandemic. Despite consumer retrenchment in other areas,… Continue reading Johnson & Johnson tops quarterly profit estimates as medical device sales jump

The U.S. is experiencing a record high in drug shortages, with 323 drugs reported in short supply in the first quarter of this year, the highest since tracking began in 2001. These shortages affect a wide range of medications, from Novo Nordisk’s weight loss drug Wegovy to cancer treatments and common antibiotics, many of which… Continue reading Healthy Returns: U.S. drug shortages reach record high, hitting Wegovy, ADHD medications